
Avidity Biosciences RNA
€ 7.72
-0.69%
Land |
|
IPO-Jahr |
2020 |
Branche |
Pharmaeinzelhändler |
Börse |
NASDAQ GLOBAL |
Anteile |
138 M |
Marktkapitalisierung |
$ 1.19 B |
EBITDA (LTM) |
$ -233 M |
P/E (LTM) |
-4.859589 |
P/S (LTM) |
204.404278 |
EPS (LTM) |
-2.92 |
Andere Aktien der Branche "Pharmaeinzelhändler"
| Name | Preis | % 24h | Marktkapitalisierung | Börse | Land | |
|---|---|---|---|---|---|---|
|
Trillium Therapeutics Inc.
TRIL
|
- | - | $ 1.94 B | Nasdaq Capital Market | ||
|
Exicure
XCUR
|
$ 0.99 | -1.7 % | $ 6.23 M | Nasdaq Capital Market | ||
|
Urovant Sciences Ltd.
UROV
|
- | - | $ 532 M | Nasdaq Global Select Market | ||
|
Acceleron Pharma Inc.
XLRN
|
- | - | $ 10.9 B | Nasdaq Global Market,SPB | ||
|
Zealand Pharma A/S
ZEAL
|
- | 0.52 % | $ 821 M | Nasdaq Global Select Market | ||
|
Zogenix, Inc.
ZGNX
|
- | -4.97 % | $ 664 M | Nasdaq Global Market,SPB | ||
|
Yunhong International
ZGYH
|
- | 0.10 % | $ 92.2 M | Nasdaq Capital Market | ||
|
ZIOPHARM Oncology, Inc.
ZIOP
|
- | -7.58 % | $ 264 M | Nasdaq Global Select Market | ||
|
Xenon Pharmaceuticals
XENE
|
$ 39.19 | 2.5 % | $ 3.11 B | Nasdaq Global Select Market | ||
|
Leap Therapeutics
LPTX
|
- | 368.57 % | $ 41.9 M | Nasdaq Global Market | ||
|
Zymeworks
ZYME
|
$ 30.93 | 2.66 % | $ 1.59 B | NYSE | ||
|
Adial Pharmaceuticals
ADIL
|
$ 3.15 | -35.42 % | $ 2.11 M | Nasdaq Capital Market | ||
|
ADMA Biologics
ADMA
|
$ 10.49 | -5.58 % | $ 2.5 B | Nasdaq Global Market | ||
|
Cortexyme
CRTX
|
- | -1.05 % | $ 67.1 M | Nasdaq Global Select Market,SPB | ||
|
Burford Capital Limited
BUR
|
$ 4.17 | 10.03 % | $ 914 M | NYSE | ||
|
Daré Bioscience
DARE
|
$ 0.65 | -0.52 % | $ 7.27 M | Nasdaq Capital Market | ||
|
Fate Therapeutics
FATE
|
$ 2.1 | 2.94 % | $ 249 M | Nasdaq Global Market,SPB | ||
|
Greenwich LifeSciences
GLSI
|
$ 16.43 | 3.2 % | $ 222 M | Nasdaq Capital Market | ||
|
Halozyme Therapeutics
HALO
|
$ 130.35 | 1.35 % | $ 15.6 B | Nasdaq Global Select Market,SPB | ||
|
Hutchison China MediTech Limited
HCM
|
$ 13.89 | 6.19 % | $ 11.9 B | Nasdaq Global Select Market | ||
|
Aptorum Group Limited
APM
|
- | - | $ 5.72 M | Nasdaq Global Select Market | ||
|
iBio
IBIO
|
$ 0.81 | -2.08 % | $ 84.3 M | NYSE American | ||
|
Kodiak Sciences
KOD
|
$ 98.19 | -0.71 % | $ 5.22 B | Nasdaq Global Market,SPB | ||
|
Karyopharm Therapeutics
KPTI
|
$ 0.09 | -0.79 % | $ 984 | Nasdaq Global Select Market | ||
|
FSD Pharma
HUGE
|
- | 5743.5 % | $ 69.7 M | Nasdaq Capital Market | ||
|
BioAtla
BCAB
|
$ 1.74 | 0.64 % | $ 102 M | Nasdaq Global Select Market | ||
|
Catalyst Pharmaceuticals
CPRX
|
- | - | $ 3.85 B | Nasdaq Capital Market | ||
|
UroGen Pharma Ltd.
URGN
|
$ 28.73 | -16.48 % | $ 1.38 B | Nasdaq Global Select Market | ||
|
Catalyst Biosciences
CBIO
|
$ 13.85 | 6.05 % | $ 1.24 B | Nasdaq Capital Market | ||
|
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | ||
|
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market | ||
|
ADiTx Therapeutics
ADTX
|
- | - | $ 374 | Nasdaq Capital Market | ||
|
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market | ||
|
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | ||
|
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | ||
|
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | ||
|
Aileron Therapeutics
ALRN
|
- | 10.36 % | $ 9.8 M | Nasdaq Global Select Market | ||
|
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | ||
|
Apellis Pharmaceuticals
APLS
|
- | - | $ 5.18 B | Nasdaq Global Select Market,SPB | ||
|
Athira Pharma
ATHA
|
- | - | $ 269 M | Nasdaq Global Select Market | ||
|
Avenue Therapeutics
ATXI
|
- | -52.27 % | $ 4.45 M | Nasdaq Global Select Market | ||
|
AVROBIO
AVRO
|
- | 1083.1 % | $ 745 M | Nasdaq Global Select Market | ||
|
AstraZeneca PLC
AZN
|
- | - | $ 96.9 B | Nasdaq Global Select Market | ||
|
Brainstorm Cell Therapeutics
BCLI
|
- | -2.5 % | $ 5.88 M | Nasdaq Capital Market | ||
|
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market | ||
|
EyePoint Pharmaceuticals
EYPT
|
$ 0.39 | -2.2 % | $ 28.6 K | Nasdaq Global Market | ||
|
Bio-Path Holdings
BPTH
|
- | - | $ 100 K | Nasdaq Capital Market | ||
|
Cara Therapeutics
CARA
|
- | -3.03 % | $ 260 M | Nasdaq Global Market,SPB | ||
|
ChromaDex Corporation
CDXC
|
- | -0.88 % | $ 598 M | Nasdaq Capital Market | ||
|
Caladrius Biosciences
CLBS
|
- | -16.75 % | $ 25.8 M | Nasdaq Capital Market |